FSA Analysis

Asset Class in Focus | 6 Jun 18

Ten years after the global financial crisis of 2008, FSA notes that pharmaceutical, healthcare and biotech stocks weathered that year better than other sectors.

Asset Class in Focus | 31 May 18

Riding China’s policy bus is not as easy as it sounds, as the poor performance of China policy-driven funds shows.

Asset Class in Focus | 22 Sep 17

Part two of a look at the hype surrounding the ESG theme finds that there are sound reasons to be skeptical about claims that ESG investments outperform the general market.

FSA Analysis | 30 Aug 17

As capital pours into green-themed funds, nobody is questioning why a growing list of ESG ‘champions’ are under investigation for involvement in a massive, multi-year environmental scandal.

FSA Analysis | 3 Nov 16

As the British government struggles to trigger an exit from the European Union, fund distribution heads at some of the biggest names in the industry share their thoughts on the implications for their UK and European operations.

Data | 4 Mar 16

How many top quartile equity funds in Asia remain there after three years? FE Advisory has crunched the numbers.

FSA Analysis | 24 Feb 16

Market volatility in the five vulnerable economies was muted during December, when US interest rates were raised.

FSA Analysis | 21 Jan 16

Funds that claim to mitigate volatility have been put to the test over the last six tumultuous months. Which ones have actually navigated well?

FSA Analysis | 24 Sep 15

An appeal to Asia’s wealth managers to create a clear and crisp distinction among themselves – or continue to see wealth leave the region.

Asset Class in Focus | 26 Aug 15

Over the last month, almost all China-dedicated equity funds have moved into the red, and there were plenty of brand names among the worst performers.